Discussion Topic: Long-Term Outcomes of Brugada Substrate Ablation: A Report from BRAVO
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women’s Hospital, is joined by guests Michael G. Katz, MD, FHRS, of Morristown Medical Center and Victor Nauffal, MD, of Brigham and Women`s Hospital, to discuss the treatment options for high-risk Brugada syndrome (BrS) with recurrent ventricular fibrillation (VF) and how it is limited. Catheter ablation is increasingly performed, but a large study with long-term outcome data is lacking. We report the results of the multicenter, international BRAVO (Brugada Ablation of VF Substrate Ongoing Registry) for treatment of high-risk symptomatic BrS. Ablation treatment is safe and highly effective in preventing VF recurrence in high-risk BrS. Prospective studies are needed to determine whether it can be an alternative treatment to implantable cardioverter-defibrillator implantation for selected patients with BrS.
Host: William H. Sauer, MD, FHRS, CCDS
Guests: Michael G. Katz, MD, FHRS and Victor Nauffal, MD
Speaker and Article Information: Download
Topic
- The Lead
Resource Type
- Podcasts
Related Resources
The Lead
Podcasts
The Lead Episode 128: A Discussion of Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial
December 4, 2025
HRX Next
Podcasts
HRX NeXt Ep. 3 – A Conversation about Understanding AI Bias in Clinical Practice
December 3, 2025
The Lead
Podcasts
The Lead Episode 127 A Discussion of Remote Screening for Asymptomatic Atrial Fibrillation: The AMALFI Randomized Clinical Trial
November 20, 2025